S.Africa's Aspen agrees drug portfolio sale to Swiss firm Acino

Credit: REUTERS/Siphiwe Sibeko

JOHANNESBURG, Oct 22 (Reuters) - South Africa's Aspen Pharmacare APNJ.J said on Friday it had agreed to sell a portfolio of six drug products to Switzerland-based Acino Pharma AG for approximately 1.8 billion rand ($123 million).

"The transaction forms part of Aspen's communicated strategy to refine its product portfolio in South Africa," the company said in a statement.

Investors had been concerned about Aspen's debt in the last two years after levels moved close to breaching debt covenants.

That prompted Aspen to sell some of its European businesses and focus more on high margin emerging markets.

Last month the company said after its annual earnings release that it was now in a comfortable debt position.

Part of the proceeds from the sale of the portfolio, which accounted for a revenue of 512 million rand in the last financial year, will be used to retire debt, it said.

Aspen and Acino will enter into a manufacturing and supply agreement in terms of which Aspen will supply the products to Acino for 7 years, it said.

The sale excludes the cost of inventory which will be additional, the company said, adding that the transaction is likely to be completed by the end of December.

($1 = 14.6363 rand)

(Reporting by Promit Mukherjee; editing by Jason Neely)

((promit.mukherjee@thomsonreuters.com; +27 64833 4448;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.